Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of dioscin in preparing medicament for preventing and treating diabetes mellitus

A technology for diabetes medicine and diosgenin is applied in the application field of diosgenin in the preparation of medicines for preventing and treating diabetes. The effect of increasing high-density lipoprotein levels

Active Publication Date: 2012-07-11
DALIAN MEDICAL UNIVERSITY
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no relevant report on the prevention and treatment of diabetes by diosgenin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dioscin in preparing medicament for preventing and treating diabetes mellitus
  • Application of dioscin in preparing medicament for preventing and treating diabetes mellitus
  • Application of dioscin in preparing medicament for preventing and treating diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Effects of Dioscin on Glucose Metabolism in HepG2 Cells Induced by High Insulin

[0013] 1.1 Drug preparation: Weigh diosgenin, dissolve it in 10% DMSO, and prepare a 1 mg / ml drug mother solution, and then dilute it with MEM to the required concentration during the experiment.

[0014] 1.2 Establish the experimental model: culture HepG2 cells with MEM medium containing 10% imported fetal cattle from Israel at 37°C, 5% CO 2 In the incubator, when the cells grew to about 80%, they were digested and passaged with 0.25% trypsin, and the HepG2 cells in the logarithmic growth phase were used for the experiment. Press 10 5 Cells were seeded in 96-well plates at a density of cells / ml. Divided into six groups, namely blank group, model group, high-dose saponin group (2.5ug / ml), middle-dose saponin group (1.25ug / ml), low-dose saponin group (0.625ug / ml), glibenclamide group (8.33ug / ml). After culturing for 24 hours until the cells adhered to the wall, except the blank group, t...

Embodiment 2

[0025] Therapeutic effect of diosgenin on rat model of type Ⅱ diabetes mellitus

[0026] 2.1 Diosgenin is used as the main drug, and various dosage forms are made according to the relevant requirements of pharmacy and clinical needs and auxiliary materials.

[0027] 2.1.1 Preparation of Dioscin Tablets

[0028] Take 100g of diosgenin, 125g of starch, 175g of lactose and 100g of microcrystalline cellulose as raw materials.

[0029] Pass the above-mentioned main ingredients and auxiliary materials through 80-mesh sieve respectively, mix well, use 5% povidone K30 (PVPK30) ethanol solution as binder, granulate with 20-mesh sieve, dry at 40-60°C, 18-mesh Sieve granules, add appropriate amount of lubricant and press into tablets, 0.5g per tablet.

[0030] 2.1.2 Preparation of dioscin capsules

[0031] Take diosgenin 100g and starch 300g.

[0032] Pass the above-mentioned main ingredients and auxiliary materials through 80-mesh sieve, mix well, use 5% povidone K30 (PVPK30) ethano...

Embodiment 3

[0052] Example 3: Therapeutic effect of diosgenin on type Ⅰ diabetes rat model

[0053] 3.1 As in Example 2, diosgenin is used as the main drug, and various dosage forms are formulated with auxiliary materials according to relevant requirements of pharmacy and clinical needs.

[0054] 3.2 Establishment of animal experimental models

[0055] Divide 50 Wistar rats (200±20g) into two groups, the blank group (16 rats), and the model group (34 rats). After one week of adaptation to feeding, they fasted for 12 hours, and intraperitoneally injected STZ (65mg / kg), the rats in the blank group were intraperitoneally injected with sodium citrate buffer (1ml / kg), and their fasting blood glucose was measured seven days later. 28 rats), were randomly divided into 3 groups (model group, diosgenin group, glibenclamide group), 9 rats in each group; and 16 rats in the blank group were randomly divided into two groups (blank group, simply administered group), 8 in each group. Both the blank ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of dioscin in preparing a medicament for preventing and treating diabetes mellitus. According to the invention, the effects of dioscin in reducing blood-sugar content of various hyperglycemia models (I-type diabetes mellitus, II-type diabetes mellitus and acute hyperglycemia caused by adrenaline) and increasing the glycogen content of the hyperglycemia models are discovered, and the effects of the dioscin in improving the cell insulin resistance caused by high insulin, reducing contents of total cholesterol, triglyceride and low-density lipoprotein, increasing content of high-density lipoprotein and regulating fat metabolism disorder are simultaneously discovered, so that the application of the dioscin in preparing the medicament for preventing and treating the diabetes mellitus is invented. Various preparations prepared from the dioscin serving as a raw material according to pharmaceutically related requirement and clinical requirement can be applied clinically, and have the advantages of safety (no toxic or side effect), convenience, economy and the like.

Description

technical field [0001] The invention relates to a new application of diosgenin, in particular to the application of diosgenin in the preparation of drugs for preventing and treating diabetes. Background technique [0002] At present, the incidence of diabetes is increasing at a rate of doubling every 15 years, and it has become the third largest disease after tumors and cardiovascular diseases. Because diabetes is accompanied by a series of complications, not only the patient feels great pain, but also brings a heavy burden to the family and the society. Therefore, finding a new drug for the prevention and treatment of diabetes with high efficiency and low toxicity is a hot research topic in the medical field. Since diabetes is divided into type Ⅰ diabetes and type Ⅱ diabetes, which are manifested as absolute insulin deficiency and insulin resistance, respectively, and type Ⅱ diabetes accounts for more than 90% of all diabetic patients, so improving insulin resistance is the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P3/10
Inventor 彭金咏吉柳汤新强许丽娜尹连红李华
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com